712 North Inc. is a California-based pharmaceutical company spearheading personalized mitochondrial medicines for patients with complex diseases, such as Alzheimer’s dementia, heart failure and cancer. Our unique approach merges mitochondria biology with pharmaceutical drug development by drugging the proteases of the mitochondrial inner membrane. These proteases are highly desired drug targets with implications for many fatal disorders. For this reason, it is necessary to profile the proteases in a person to select the right treatment rather than relying on a medical diagnosis. This is engrained in 712 North’s mission statement personalized mitochondrial medicines. Positioned as pathway-company rather than focusing on a certain disease, we are poised to be first-in-class.

In a nutshell...

Our screening platform

712 North company presentation at the BIO Investor Forum 2019 in San Francisco, CA

712 North company presentation at the Hello Tomorrow Challenge 2017 in Paris, France

Follow us on twitter

Like us on facebook

Connect with us on LinkedIn

Write us an e-mail

Chat with us on WeChat